查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929572

全球腹主動脈腹部主動脈血管瘤血管支架系統市場（依器械類型、動脈瘤類型、手術類型和最終用戶分類）預測，2026-2032年

Endovascular AAA Stent Graft System Market by Device Type, Aneurysm Type, Procedure Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腹部主動脈血管瘤血管支架物系統市值將達到 11.2 億美元，到 2026 年將成長至 12.1 億美元，到 2032 年將達到 18.3 億美元，複合年成長率為 7.17%。

主要市場統計數據
基準年 2025 11.2億美元
預計年份：2026年 12.1億美元
預測年份：2032年 18.3億美元
複合年成長率 (%) 7.17%

本文概述了推動血管支架應用的技術進步、臨床工作流程和相關人員的期望。

腹部主動脈血管瘤的血管內修復術已從一種創新替代方案發展成為血管外科的核心支柱，這得益於器械設計、影像引導和手術全期管理技術的進步。如今，臨床醫師期望血管支架系統能夠在適應不同動脈瘤解剖結構和病患合併症的同時，兼顧貼合度、輸送精準度和長期耐久性。因此，器械研發人員和醫療服務提供者正攜手合作，致力於開發能夠降低手術複雜性、縮短住院時間並改善病患短期和長期預後的解決方案。

器械設計、影像導引規劃和傳輸模式的創新正在從根本上重塑腹部主動脈血管瘤（AAA）血管內治療的臨床管道和應用趨勢。

血管內動脈瘤修復領域正經歷變革性的轉變，涵蓋器械創新、手術操作和醫療保健系統政策等各個層面。器械設計的進步如今更加重視模組化和患者個人化，使臨床醫生能夠更精準地處理腎旁動脈瘤和胸腹主動脈瘤等複雜解剖結構。影像和規劃軟體也在同步發展，實現了3D手術模擬和更精確的著陸區評估，從而減少了術中意外情況，並使器械選擇與解剖結構要求更加匹配。

本文全面檢驗了近期美國貿易行動對供應鏈韌性、籌資策略以及臨床應用血管內主動脈裝置的影響。

2025年推出的貿易政策變化給依賴全球供應鏈獲取血管支架組件、無菌包裝和專用輸送工具的公司和醫療機構帶來了新的挑戰。關稅調整可能會增加進口原料和成品的到岸成本，改變全球製造地的經濟格局，並促使採購團隊重新評估與供應商的關係。這些連鎖反應將波及諸多領域，包括生產速度、庫存管理以及供應商與醫院供應鏈團隊之間協商的合約條款。

從詳細的分割觀點出發，將器械分類、動脈瘤解剖結構、治療環境和手術緊急程度與臨床需求和商業策略聯繫起來。

了解細分市場的細微差別對於協調臨床能力、產品系列和商業性策略至關重要。在評估諸如穿支血管移植、髂動脈分支血管移植和標準血管移植等器械分類時，可以清楚地看到，每一類都針對不同的解剖和治療需求。穿支血管移植旨在處理腎動脈附近的血管分支，需要精確的術前規劃和客製化尺寸。而髂動脈分支血管移植則專注於維持涉及髂總動脈的動脈瘤中的髂內動脈血流。標準血管移植在簡單的腎臟下解剖結構中仍然至關重要，因為現成的解決方案可以簡化物流和手術準備。

對醫療基礎設施、報銷制度和臨床能力對重點地區醫療服務採用趨勢的影響進行比較評估

地理位置對血管內介入治療的普及模式、監管管道和臨床服務結構有顯著影響。美洲地區擁有成熟的血管內介入治療項目，並致力於擴大社區醫院和門診中心的覆蓋範圍，其完善的報銷體系鼓勵了手術的普及。此外，該地區的臨床群體累積了大量真實世界數據，製造商和醫療系統可以利用這些數據來不斷改進器械，並制定循證的推廣通訊協定。

從公司層面來看，實證差異化、策略夥伴關係和服務能力備受重視，這些因素會影響臨床醫師招募和採購決策。

血管內血管支架領域的企業競爭格局取決於產品差異化、臨床證據的累積以及透過培訓和服務來支持臨床醫生的能力。成熟的全球醫療設備製造商擁有足夠的生產規模、監管方面的專業知識和廣泛的商業性網路，能夠支援多中心註冊研究和長期療效研究。而專注於血管醫療設備的製造商則更著重於技術差異化、快速改進輸送系統以及與高容量中心密切合作，以提升器械在複雜解剖結構中的應用能力。

整合產品開發、臨床培訓、供應鏈韌性和支付方合作的策略和營運建議，以加速永續應用。

行業領導者應採取組合式策略，使產品開發、臨床證據和商業性執行與醫療服務提供者和患者不斷變化的需求保持一致。投資於能夠適應不同解剖結構的模組化設備平台，既能擴大臨床覆蓋範圍，又能降低庫存管理的複雜性。同時，他們應優先考慮完善的上市後證據項目和註冊登記，以檢驗長期療效，並為與支付方就價值導向方案的討論提供支持。

本報告清楚描述了用於得出研究結果的證據來源和分析方法，包括臨床醫生訪談、監管資訊綜合和檢驗通訊協定。

本執行摘要的研究以對血管外科醫生、介入放射科醫生、採購人員和供應鏈主管的定性調查為基礎，並結合對監管申報文件、臨床實驗室數據和同行評審文獻的系統分析。主要研究結果透過結構化訪談和專家小組討論收集，確保高容量中心、門診手術機構和血管專科計畫的代表均有參與，從而涵蓋營運多樣性和臨床觀點。

最終綜合分析將技術進步、臨床實務變革和商業性需求整合起來，為相關人員得出策略性結論。

技術創新、不斷演進的醫療服務模式以及監管要求的交匯融合，正在重塑腹部主動脈血管瘤內治療的格局。器械朝向模組化和解剖結構特異性解決方案的演進，使臨床醫生能夠更精準地治療更複雜的解剖結構，而影像規劃工具則降低了術中不確定性。這些臨床進展，加上營運模式的轉變（將合適的病例轉移到門診和專科中心），對器械組合和臨床醫生培訓提出了新的要求。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 依器械類型分類的腹部主動脈血管瘤血管支架系統市場

  • 窗戶類型
  • 髂動脈分支類型
  • 標準型

9. 依動脈瘤類型分類的腹部主動脈血管瘤血管支架系統市場

  • 腎下動脈類型
  • 腎臟旁型
  • 在腎動脈上
  • 胸腹部

10. 依手術類型分類的腹部主動脈血管瘤血管支架系統市場

  • 擇期手術
  • 緊急狀況

第11章 依最終用戶分類的腹部主動脈血管瘤血管支架系統市場

  • 門診手術中心
  • 醫院
  • 血管專科中心

12.腹部主動脈血管瘤血管支架系統市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 依組別分類的腹部主動脈血管瘤血管支架系統市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國腹部主動脈血管瘤血管支架系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國腹主動脈腹部主動脈血管瘤血管支架系統市場

17. 中國腹部主動脈血管瘤血管支架系統市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bentley InnoMed GmbH
  • Bolton Medical, Inc.
  • Boston Scientific Corporation
  • Braile Biomedica Industria e Comercio SA
  • CR Bard, Inc.
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Cordis Corporation
  • CryoLife, Inc.
  • Endologix, Inc.
  • Getinge AB
  • Jotec GmbH
  • LeMaitre Vascular, Inc.
  • Lombard Medical, Inc.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • Shanghai MicroPort Endovascular MedTech Group Co., Ltd.
  • Terumo Corporation
  • TriVascular Technologies, Inc.
  • Vascutek Ltd.
  • WL Gore & Associates, Inc.
Product Code: MRR-0A3806951827

The Endovascular AAA Stent Graft System Market was valued at USD 1.12 billion in 2025 and is projected to grow to USD 1.21 billion in 2026, with a CAGR of 7.17%, reaching USD 1.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.12 billion
Estimated Year [2026] USD 1.21 billion
Forecast Year [2032] USD 1.83 billion
CAGR (%) 7.17%

Contextual overview that situates technological advances clinical workflows and stakeholder expectations driving modern endovascular AAA stent graft implementation

Endovascular repair of abdominal aortic aneurysms has moved from an innovative alternative to a core pillar of vascular surgery practice, driven by advances in device design, imaging guidance, and perioperative management. Clinicians now expect stent graft systems to balance conformability, delivery precision, and long-term durability while accommodating diverse aneurysm anatomies and patient comorbidities. As a result, device developers and healthcare providers are aligning around solutions that reduce procedural complexity, shorten hospital stays, and improve short- and long-term patient outcomes.

At the same time, hospitals and specialty centers are recalibrating operational pathways to integrate hybrid operating environments, advanced preoperative planning tools, and multidisciplinary teams. These shifts create both opportunities and responsibilities for stakeholders across the value chain. Manufacturers must invest in clinical evidence and training, while providers must adapt procurement strategies and clinical workflows. In parallel, payers and health systems increasingly emphasize value-based metrics and post-market surveillance, prompting greater collaboration between clinical leaders and industry to demonstrate real-world effectiveness and safety.

This introduction frames the subsequent sections by outlining the technical, clinical, and organizational factors that determine adoption and sustained use of endovascular stent graft systems. By foregrounding patient-centered outcomes and operational feasibility, stakeholders can better prioritize investments and partnerships that drive reliable, reproducible care for aneurysm patients.

How innovation in device design imaging guided planning and care delivery models is fundamentally reshaping clinical pathways and adoption dynamics in endovascular AAA care

The landscape of endovascular aneurysm repair is undergoing transformative shifts that span device innovation, procedural practice, and health system policy. Advances in device design now prioritize modularity and patient-specific customization, allowing clinicians to address complex anatomies such as juxtarenal and thoracoabdominal aneurysms with greater precision. Imaging and planning software have evolved in parallel, enabling three-dimensional procedural simulations and more accurate landing-zone assessments, thereby reducing intraoperative surprises and improving alignment between device selection and anatomical demands.

Concurrently, care delivery models are shifting toward less invasive pathways with an emphasis on same-day or short-stay procedures where clinically appropriate. Ambulatory surgery centers and specialty vascular centers are increasingly equipped to perform elective endovascular repairs, which changes demand patterns for inventory, training, and device configurations. Moreover, the growth of endovascular expertise among vascular surgeons and interventional radiologists has broadened procedural indications and refined patient selection criteria, improving outcomes for appropriately selected patients.

Financial and regulatory pressures are also reshaping innovation incentives. Payers are demanding robust real-world evidence and long-term outcome data, which in turn drives manufacturers to invest in registries, post-market studies, and health economic analyses. Together, these technological, clinical, and policy-driven forces are redefining competitive differentiation in the field and setting a higher bar for safety, effectiveness, and cost-efficiency.

Comprehensive examination of how recent United States trade measures influence supply chain resilience procurement strategy and clinical access to endovascular aortic devices

Trade policy shifts introduced in 2025 have introduced a new layer of complexity for companies and healthcare providers that rely on global supply chains for stent graft components, sterile packaging, and specialized delivery tools. Tariff changes can increase landed costs for imported raw materials and finished devices, alter the economics of global manufacturing footprints, and prompt procurement teams to reassess supplier relationships. These ripple effects are felt across manufacturing cadence, inventory management, and contracting terms negotiated between suppliers and hospital supply chain teams.

As tariffs create pressure on unit costs, manufacturers may pursue a range of strategic responses including partial vertical integration of critical component production, selective regional manufacturing, and nearshoring to mitigate exposure to cross-border duties. From the provider perspective, purchasing groups and health systems will intensify price benchmarking and may shift toward longer-term agreements that stabilize unit pricing and guarantee supply continuity. At the same time, clinical teams must anticipate potential changes to device availability and plan accordingly to avoid procedural delays, especially for urgent and emergency cases.

Regulatory oversight and reimbursement dynamics will further mediate these impacts. Payers examining overall treatment costs may apply greater scrutiny to device selection and perioperative pathways, accelerating adoption of cost-effective clinical protocols. In short, tariffs alter commercial calculus and operational planning across the value chain, necessitating proactive supply chain resilience and price management strategies to preserve access and maintain care quality.

Detailed segmentation perspective linking device classes aneurysm anatomies care settings and procedural urgency to clinical requirements and commercial strategies

A nuanced view of segmentation is essential for aligning clinical capabilities with product portfolios and commercial approaches. When assessing device type categories such as fenestrated, iliac branch, and standard grafts, it becomes clear that each class addresses distinct anatomic and therapeutic needs. Fenestrated devices are engineered to accommodate branch vessels near the renal arteries, demanding precise preoperative planning and customized sizing, while iliac branch solutions focus on preserving hypogastric flow in aneurysms involving the common iliac artery. Standard grafts remain indispensable for straightforward infrarenal anatomies where off-the-shelf solutions can simplify logistics and procedural setup.

Anatomy-driven segmentation across infrarenal, juxtarenal, suprarenal, and thoracoabdominal aneurysm types carries critical implications for device selection, procedural risk profiles, and perioperative resource allocation. Juxtarenal and suprarenal anatomies frequently require adjunctive maneuvers or advanced device features to secure adequate proximal fixation, while thoracoabdominal cases often necessitate hybrid approaches and multidisciplinary planning. These complexity gradients influence inventory strategies and clinician training priorities.

End-user segmentation among ambulatory surgery centers, hospitals, and specialty vascular centers highlights divergent operational models. Ambulatory settings emphasize throughput and simplified device configurations that support rapid turnover, whereas hospitals and specialty centers must maintain the capability to manage high-complexity cases and emergencies. Procedure-type segmentation between elective and emergency interventions further dictates device availability, with emergency workflows requiring immediate access to versatile, reliable graft options and protocols to support rapid decision-making. Collectively, these segmentation lenses inform product design imperatives, clinical training investments, and commercial engagement models.

Regional comparative assessment describing how healthcare infrastructure reimbursement and clinical capacity drive varied adoption trajectories across major global regions

Geographic dynamics materially affect adoption patterns, regulatory pathways, and the structure of clinical services. In the Americas, established endovascular programs coexist with initiatives that expand access into community hospitals and ambulatory centers, and the region benefits from well-developed reimbursement frameworks that facilitate procedural uptake. Clinical communities in this region also generate large volumes of real-world data, which manufacturers and health systems use to inform iterative device improvements and evidence-based adoption protocols.

Across Europe Middle East & Africa, regulatory diversity and heterogeneous reimbursement policies shape a mosaic of adoption speeds and clinical practices. Certain European markets emphasize rigorous health technology assessment and comparative effectiveness data, while other countries prioritize rapid access to innovation through conditional pathways. In many parts of the Middle East and Africa, investment in vascular infrastructure is rising, creating opportunities for targeted product deployment and training partnerships that build local procedural capacity.

Asia-Pacific exhibits a broad spectrum of capabilities, from highly advanced tertiary centers in urban hubs to regions where infrastructure investment is accelerating. Countries in this region are notable for rapid adoption of minimally invasive techniques and for fostering local manufacturing ecosystems. Regional differences in population demographics, prevalence of comorbid disease, and hospital infrastructure lead to distinct product requirements and service models, creating both challenges and opportunities for companies seeking sustainable regional strategies.

Company-level perspective emphasizing evidence-driven differentiation strategic partnerships and service capabilities that influence clinician adoption and procurement decisions

Competitive dynamics among companies in the endovascular stent graft space are shaped by product differentiation, clinical evidence generation, and the ability to support clinicians through training and service. Established global medical device manufacturers bring scale in manufacturing, regulatory expertise, and broad commercial reach, enabling them to support multicenter registries and longitudinal outcome studies. At the same time, specialized vascular device companies focus on technical differentiation, rapid iteration of delivery systems, and close collaboration with high-volume centers to refine device features for complex anatomies.

Strategic alliances and targeted acquisitions are common mechanisms to expand device portfolios, access complementary technologies, or accelerate geographic reach. Companies that prioritize real-world evidence, structured training programs for implanters, and comprehensive clinical support are better positioned to demonstrate value to payers and institutions. Additionally, service-oriented offerings such as digital planning platforms, proctorship networks, and integrated sterilization and logistics solutions enhance competitive positioning by reducing barriers to adoption for hospitals and specialty centers.

From a commercial standpoint, successful players balance investment in innovation with pragmatic attention to supply chain reliability and pricing transparency. Those that can translate clinical benefits into demonstrable improvements in perioperative efficiency, patient outcomes, and total episode costs will maintain durable relationships with healthcare systems and proceduralists.

Strategic and operational recommendations that align product development clinical training supply chain resilience and payer engagement to accelerate sustainable adoption

Industry leaders should take a portfolio approach that aligns product development, clinical evidence, and commercial execution with the evolving needs of providers and patients. Invest in modular device platforms that can be configured for a range of anatomies, thereby reducing inventory complexity while expanding clinical applicability. Parallel efforts should prioritize robust post-market evidence programs and registries to validate long-term outcomes and support payer discussions focused on value.

Strengthen supply chain resilience through diversification of component sources and selective regionalization of manufacturing to mitigate tariff exposure and shorten lead times. Engage early and collaboratively with high-volume clinical centers to co-design training curricula and simulation-based proctoring that accelerate safe clinician proficiency. In addition, develop clear pathways for ambulatory adoption by packaging device offerings with streamlined procedural checklists and logistics solutions that support fast turnover without compromising safety.

Finally, cultivate payer partnerships by aligning clinical evidence with health economic analyses that demonstrate impact on length of stay, complication reduction, and downstream resource utilization. By synchronizing product innovation, clinician enablement, and reimbursement strategy, manufacturers and providers can jointly expand appropriate access to endovascular solutions while maintaining fiscal sustainability.

Clear explanation of the evidence sources and analytic approach including clinician interviews regulatory synthesis and triangulation protocols used to develop the report insights

The research underpinning this executive summary combined primary qualitative engagement with vascular surgeons, interventional radiologists, procurement leaders, and supply chain executives alongside systematic synthesis of regulatory filings, clinical trial data, and peer-reviewed literature. Primary insights were gathered through structured interviews and expert panels, ensuring representation from high-volume centers, ambulatory surgery environments, and specialty vascular programs to capture operational diversity and clinical perspectives.

Secondary research involved targeted review of regulatory approvals, device labeling, and published outcomes studies to triangulate evidence on device performance, procedural workflows, and post-market surveillance findings. Data synthesis emphasized cross-validation between clinician experience and documented clinical outcomes to reduce bias. The methodology also incorporated scenario analysis to assess the operational implications of supply chain disruptions and policy changes on device availability and procurement strategies.

Throughout the research process, findings were iteratively reviewed with clinical advisors and industry stakeholders to refine conclusions and ensure practical applicability. The resulting insights reflect a blend of qualitative clinician judgment and documented clinical data, providing a balanced foundation for strategic decision-making.

Closing synthesis that aligns technological progress clinical practice transformation and commercial imperatives into a cohesive set of strategic conclusions for stakeholders

The confluence of technological innovation, evolving care delivery models, and regulatory expectations is reshaping the landscape for endovascular abdominal aortic aneurysm interventions. Device evolution toward modularity and anatomically tailored solutions is enabling clinicians to treat increasingly complex anatomies with greater precision, while imaging and planning tools reduce intraoperative uncertainty. These clinical advances are complemented by operational shifts that move appropriate cases into ambulatory and specialty settings, creating new demands for device portfolios and clinician training.

At the same time, external pressures such as tariff changes and payer emphasis on value compel manufacturers and providers to invest in supply chain resilience, rigorous post-market evidence, and demonstrable cost-effectiveness. Regional heterogeneity requires nuanced strategies that reflect local regulatory frameworks, infrastructure maturity, and provider capabilities. For industry leaders, success will depend on integrating product innovation with practical service offerings, targeted clinical support, and clear health economic narratives.

In summary, stakeholders who prioritize adaptable device platforms, clinician enablement, and robust evidence-generation will be best positioned to enhance patient outcomes while navigating commercial and operational headwinds in the evolving endovascular AAA environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endovascular AAA Stent Graft System Market, by Device Type

  • 8.1. Fenestrated
  • 8.2. Iliac Branch
  • 8.3. Standard

9. Endovascular AAA Stent Graft System Market, by Aneurysm Type

  • 9.1. Infrarenal
  • 9.2. Juxtarenal
  • 9.3. Suprarenal
  • 9.4. Thoracoabdominal

10. Endovascular AAA Stent Graft System Market, by Procedure Type

  • 10.1. Elective
  • 10.2. Emergency

11. Endovascular AAA Stent Graft System Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Vascular Centers

12. Endovascular AAA Stent Graft System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endovascular AAA Stent Graft System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endovascular AAA Stent Graft System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endovascular AAA Stent Graft System Market

16. China Endovascular AAA Stent Graft System Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. B. Braun Melsungen AG
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bentley InnoMed GmbH
  • 17.9. Bolton Medical, Inc.
  • 17.10. Boston Scientific Corporation
  • 17.11. Braile Biomedica Industria e Comercio S.A.
  • 17.12. C.R. Bard, Inc.
  • 17.13. Cardinal Health, Inc.
  • 17.14. Cook Medical LLC
  • 17.15. Cordis Corporation
  • 17.16. CryoLife, Inc.
  • 17.17. Endologix, Inc.
  • 17.18. Getinge AB
  • 17.19. Jotec GmbH
  • 17.20. LeMaitre Vascular, Inc.
  • 17.21. Lombard Medical, Inc.
  • 17.22. Medtronic plc
  • 17.23. Meril Life Sciences Pvt. Ltd.
  • 17.24. Merit Medical Systems, Inc.
  • 17.25. MicroPort Scientific Corporation
  • 17.26. Shanghai MicroPort Endovascular MedTech Group Co., Ltd.
  • 17.27. Terumo Corporation
  • 17.28. TriVascular Technologies, Inc.
  • 17.29. Vascutek Ltd.
  • 17.30. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY FENESTRATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY FENESTRATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY FENESTRATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ILIAC BRANCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ILIAC BRANCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ILIAC BRANCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY INFRARENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY INFRARENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY INFRARENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY JUXTARENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY JUXTARENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY JUXTARENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUPRARENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUPRARENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUPRARENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY THORACOABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY THORACOABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY THORACOABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ELECTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ELECTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ELECTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY EMERGENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY EMERGENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY EMERGENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)